The ILux compared to the mechanical meibomian gland expression for the treatment of moderate and severe meibomian gland dysfunction.

Aim: To compare the safety and effectiveness of eyelid treatment with the ILux-MGD Treatment System in one session versus five sessions of mechanical meibomian gland expression (MMGE) in patients with moderate to severe meibomian gland dysfunction (MGD).

Methods: A prospective, randomized, open-label, and controlled clinical trial that compared one session of the ILux MGD Treatment System versus five sessions of MMGE in both eyes of 130 patients aged ≥18y with Ocular Surface Disease Index (OSDI) scores ≥13, total meibomian gland scores (MGS) of <15 in the lower eyelid of each eye, and non-invasive tear break-up time (NI-TBUT) <10s, who were randomized 1:1 to ILux or MMGE.

Results: The mean age was 58±17.